<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03134261</url>
  </required_header>
  <id_info>
    <org_study_id>DIMAB</org_study_id>
    <nct_id>NCT03134261</nct_id>
  </id_info>
  <brief_title>Diagnostic Imaging of Bone Metastases in Prostate Cancer Patients</brief_title>
  <acronym>DIMAB</acronym>
  <official_title>A Prospective Study Comparing the Diagnostic Accuracy of Bone SPECT-CT, Choline-PET-CT, PSMA-PET-CT, NaF-PET-CT and WB-MRI in the Detection of Prostate Cancer Bone Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An improved diagnosis of bone metastases in prostate cancer patients can have a significant
      impact on treatment strategy and probably survival as well.

      The primary purpose of the project is to determine the diagnostic accuracy of bone SPECT-CT,
      choline-PET-CT, PSMA-PET-CT, NaF-PET-CT and Whole-body MRI in the diagnosis of bone
      metastases in prostate cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The project is a prospective diagnostic test accuracy study. The project takes place at
      Herlev Hospital and is a collaboration between the Department of Radiology and the Department
      of Clinical Physiology and Nuclear Medicine.

      The investigators want to include 300 prostate cancer patients referred to our standard
      diagnostic imaging (NaF-PET-CT scan) by the clinicians.

      In addition to the standard diagnostic imaging (NaF-PET-CT-scan), two project will be
      performed on all participants. The project has three arms with the following scanning
      combinations:

      A) Whole-body MRI + SPECT-CT B) Whole-body MRI + Cholin-PET-CT C) Whole-body MRI +
      PSMA-PET-CT The recruitment of project participants takes place on the day when the patients
      are undergoing a NaF-PET-CT scan in the course of regular clinical practice at our
      institution.

      All readers are experienced radiologists or specialists in nuclear medicine. Patient
      identification on each scan will be anonymized and the reader will not have access to
      clinical and biochemical information or previous imaging studies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2014</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Study participants will be allocated to the &quot;ongoing project arm&quot; at the time of enrollment.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic accuracy</measure>
    <time_frame>The two project scans will be performed within a maximum of 30 days from the performance of the NaF-PET-CT scan</time_frame>
    <description>Sensitivity and specificity</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Prostate Cancer Metastatic to Bone</condition>
  <arm_group>
    <arm_group_label>SPECT-CT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The participants will undergo two project scans: WB-MRI and SPECT-CT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cholin-PET-CT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The participants will undergo two project scans: WB-MRI and Cholin-PET-CT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PSMA-PET-CT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The participants will undergo two project scans: WB-MRI and PSMA-PET-CT</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>WB-MRI</intervention_name>
    <description>scanning methods</description>
    <arm_group_label>SPECT-CT</arm_group_label>
    <arm_group_label>Cholin-PET-CT</arm_group_label>
    <arm_group_label>PSMA-PET-CT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>SPECT-CT</intervention_name>
    <description>scanning methods</description>
    <arm_group_label>SPECT-CT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cholin-PET-CT</intervention_name>
    <description>scanning methods</description>
    <arm_group_label>Cholin-PET-CT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PSMA-PET-CT</intervention_name>
    <arm_group_label>PSMA-PET-CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        A subject will be eligible for project participation if he meets all of the following
        criteria:

          -  Is either 1) a newly diagnosed prostate cancer patient in clinical suspicion of bone
             metastases or 2) a previously diagnosed prostate cancer patient in clinical suspicion
             of progression in the form of bone metastases. The subject must have been referred to
             the standard diagnostic imaging (18F-NaF-PET-CT) at our institution for bone
             metastases.

          -  The prostate cancer diagnosis must be biopsy-proven

          -  The subject is willing and able to comply with the protocol as judged by the
             investigator

        Exclusion Criteria:

        A subject will be excluded from the protocol if he meets one or more of the following
        criteria:

          -  Has prior malignancy, except for adequately treated basal cell or squamous cell skin
             cancer

          -  Has pacemaker or implanted devices (eg. cardiac valves, neurostimulator or insulin
             pump) that cannot be removed, metal clips/metal prostheses from surgery that are not
             MRI compatible or metallic foreign bodies in the eye (MRI exclusion criteria)

          -  Has any condition that places the subject at an unacceptable risk if he undergoes a
             diagnostic CT-scan (e.g. history of severe allergic reaction to the contrast agent).

          -  Has severe obesity (&gt;195 kg is the weight limit for the scanner table)

          -  Has severe claustrophobia
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Only males can get prostate cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik S. Thomsen, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Department of Radiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eva Dyrberg Mortensen, MD</last_name>
    <phone>+45 38681002</phone>
    <email>eva.dyrberg@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Henrik S. Thomsen, Professor</last_name>
    <phone>+45 38683212</phone>
    <email>henrik.thomsen@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Radioogy/Department of Nuclear Medicine</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Dyrberg Mortensen, MD</last_name>
      <phone>+45 38681002</phone>
      <email>eva.dyrberg@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Henrik S Thomsen, Professor</last_name>
      <phone>+45 38681002</phone>
      <email>henrik.thomsen@regionh.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2017</study_first_submitted>
  <study_first_submitted_qc>April 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2017</study_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Eva Dyrberg Mortensen</investigator_full_name>
    <investigator_title>MD, Phd-student</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

